Medicinal agents in this category are commonly used for the relief of internal haemorrhoids and other associated ano-rectal conditions. Анузол is generally considered relevant in therapeutic areas where short-term symptomatic assistance is needed, primarily for conditions presenting with disruptive symptom manifestations. It is applied across domains where additional symptomatic support for symptoms related to physical discomfort is required, including uncomplicated hemorrhoids, minor anal fissures, and inflammatory states characterized by periods of heightened symptoms.

The primary symptomatic role involves supporting the management of sensory and functional discomfort. The medication is used for managing symptom clusters that may become intense or disruptive, helping patients cope more steadily with symptom fluctuations. It is often used during phases when symptoms become more noticeable, such as during acute flare-ups or for localized discomfort that intensifies following a bowel movement.

Quick Fact: Relief for Pain, Itching, and Spasm

Relief of Key Symptom Clusters

Анузол assists in addressing symptoms that cluster into patterns requiring supportive management. It addresses symptom clusters that are relevant for easing localized discomfort and burning, supporting the management of persistent itching and irritation, and easing symptoms related to uncomfortable smooth muscle tension. This multi-symptom support contributes to easing the overall symptom load.

Eligibility Scope: Who Can Use Анузол

Use of Анузол (Belladonna/Bismuth/Zinc Sulfate) is established for Adults (18 years and older).

Populations for Whom Use is Not Recommended:

• Pediatric Population: Use is formally not recommended in children under 18 years, as safety and efficacy have not been established by regulators.
• Pregnancy and Lactation: Use is not recommended during pregnancy or breastfeeding, a restriction driven by the Belladonna component and insufficient safety data.

Official Contraindications

The medicine is contraindicated and must not be used by specific patient populations as defined in regulatory labeling:

• Hypersensitivity: Known allergy to any active substance or excipient.
• Glaucoma: Specifically angle-closure glaucoma.
• Gastrointestinal (GI) and Urinary Obstruction: Conditions such as Obstructive GI Disease (e.g., paralytic ileus) or Obstructive Uropathy.
• Myasthenia Gravis.
• Severe Organ Dysfunction: Patients with Severe Hepatic Disease (Liver failure) or Severe Renal Disease (Kidney failure).

Eligibility-Related Restrictions

Use requires caution in the Elderly due to potential increased sensitivity to systemic effects. Patients experiencing Rectal Bleeding or blood in the stool must consult a healthcare professional before use, as this may indicate a more serious underlying disorder.

Connection to the Overall Eligibility Profile

The official regulatory profile strictly limits eligibility to generally healthy adults without specific contraindicating conditions. The contraindications are defined primarily by the product's anticholinergic component and the mandatory requirement for adequate liver and kidney function for proper component clearance.

Interactions with other medicines and products

The interaction profile for Анузол is primarily determined by its Belladonna alkaloid component, which is classified as an anticholinergic agent. Government regulatory documents establish specific restrictions and warnings based on pharmacodynamic effects and altered gastrointestinal motility.

Contraindicated and Restricted Combinations

Official labeling restricts co-administration with oral Potassium Chloride preparations, particularly those formulated as wax-matrix tablets. This restriction is based on the increased risk of gastrointestinal lesion formation, which is linked to the Belladonna component slowing down intestinal transit time.

Pharmacodynamic and Additive Interactions

Co-administration with other anticholinergic medicines (such as certain antidepressants or antihistamines) is documented to result in an additive effect, increasing the potential for anticholinergic-related adverse outcomes. Similarly, combining with CNS depressants, including alcohol, may potentiate the risk of central nervous system effects, such as drowsiness or sedation, as stated in official warnings. Conversely, the anticholinergic action may result in pharmacodynamic antagonism against the efficacy of prokinetic agents, which are designed to increase gastrointestinal motility.

Administration Requirements and Special Populations

Regulatory guidance specifies a mandatory timing separation when co-administering with antacids or specific antidiarrheals to avoid interference with absorption. Furthermore, the regulatory profile includes a caution that elderly patients may exhibit an increased susceptibility to CNS effects when Анузол is co-administered with other interacting agents.

Анузол, when formulated with the corticosteroid hydrocortisone acetate, functions as a glucocorticoid receptor (GR) agonist. Upon topical administration to the anorectal mucosa, the active moiety, hydrocortisone, translocates into target cells and binds to the cytosolic GR. This ligand-receptor complex subsequently dimerizes and translocates to the cell nucleus, where it acts as a transcription factor. It modulates gene expression by binding to glucocorticoid response elements (GREs) on the promoter regions of various genes. Key downstream effects include the transactivation of genes coding for anti-inflammatory proteins, such as annexin A1 (lipocortin-1), which inhibits phospholipase A2 activity. Concurrently, the complex mediates transrepression by interfering with the activity of pro-inflammatory transcription factors, including NF-kappa B and AP-1. This dual transcriptional modulation decreases the synthesis of pro-inflammatory mediators, including prostaglandins, leukotrienes, and cytokines. At the system level, the mechanism promotes local vasoconstriction and suppresses the cellular and humoral components of the inflammatory response, resulting in localized cellular process stabilization.

The use of Анузол is governed by specific administration parameters, primarily due to its localized action and the inclusion of the Belladonna alkaloid component. This information establishes the standardized usage of the product.

Official Administration Guidelines

The standard usage protocol is structured to ensure proper local contact and adherence to systemic limits, based on the unique multicomponent nature of the suppository. The administration regimen mandates the rectal route and ties the timing of insertion to a prior bowel evacuation, which serves as a key procedural condition for its intended use. The daily frequency and the overall duration of the treatment define the strict, standardized scope of its application, ensuring that use patterns align with established frequency and total exposure constraints. These parameters are defined within the product specifications for the medicinal product.

Research Evidence / Overview of Studies for Анузол

Evidence for Symptomatic Management of Uncomplicated Hemorrhoids

The evidence for this specific multi-component preparation, which includes Belladonna extract, Tribromphenolate Bismuth, and Zinc Sulfate, is drawn from its long history of regulatory inclusion and the research conducted on related traditional anti-hemorrhoidal compounds. Research has explored how symptoms change over time in adult patients experiencing uncomplicated hemorrhoids. These studies often involved short-term randomized controlled trials (RCTs) applied in research examining patient-reported experiences of discomfort. Researchers monitored patient-reported outcomes describing perceived discomfort, focusing on outcomes related to physical discomfort such as localized pain, burning, and itching (pruritus).

Regulatory summaries note the established pharmacological profile of the Belladonna component, which research has explored in relation to smooth muscle tension that may accompany anorectal conditions. However, the specific combination found in Анузол lacks a large volume of dedicated, modern RCTs. The data used by regulatory bodies often contribute to the broader evidence landscape but may rely on studies of similar formulas. Certainty remains low regarding definitive findings for this exact formulation, meaning the evidence contributes to understanding symptom patterns but research does not determine whether an individual will respond similarly.

Evidence for Symptomatic Relief of Minor Anal Fissures

Research was studied for its use in conditions involving periods of heightened symptoms, such as minor anal fissures and other acute ano-rectal irritation. Studies explored how symptoms evolved in the observed populations, with a focus on outcomes capturing phases of heightened symptom activity, such as localized pain severity and overall irritation.

Evidence is limited in this area, primarily because the studies conducted during periods of increased symptom activity are often short-term and results apply only to the populations studied. Comparative evidence against modern, specialized therapies for anal fissures is lacking. Therefore, the research provides context but not individual predictions, and data are still emerging regarding the most effective research approaches for this specific use.

What is Still Uncertain About Анузол (Research Gaps)

The primary uncertainty involves the lack of dedicated, high-quality RCTs specifically for the combination of Belladonnae Folia Extract, Tribromphenolate Bismuth, and Zinc Sulfate. Key research limitations include the fact that follow-up durations were limited, meaning that long-term outcomes are not well characterized. Comparative evidence is lacking against modern standards of care, and sample sizes were modest in many of the older or related trials.

Key Studies & References

1. Belladonna Alkaloids and Anticholinergic Agents (Pharmacological Class Information)

Common questions about Анузол (FAQ)

Q: Is Анузол the same as other medicines for the same condition?

A: Official regulatory information describes Анузол as a distinct combination medicinal product. It contains a tripartite blend of three active ingredients: Belladonnae Folia Extract, Tribromphenolate Bismuth, and Zinc Sulfate. This specific combination of herbal and mineral components distinguishes the product from other single-ingredient or dual-agent preparations available for similar conditions.

Q: Can Анузол interact with supplements or herbal remedies?

A: The official product information addresses interactions primarily with certain medicines, such as other anticholinergic medicines and alcohol. Regulatory guidance often addresses co-administration with other substances, including dietary supplements or herbal products. Official labeling provides information to help assess the potential for combined or antagonistic effects.

Q: Are there any official reports of serious side effects from Анузол?

A: Official regulatory documentation outlines the potential for rare, serious reactions that have been acknowledged in the safety profile. These include the potential for severe systemic hypersensitivity reactions (allergic reactions) or the development of Acute Angle-Closure Glaucoma in susceptible individuals.

Q: Is there any research that supports the use of Анузол?

A: Studies and official information describe that research has examined patient-reported outcomes for symptomatic relief in adults experiencing uncomplicated hemorrhoids and minor anal fissures. These studies monitored perceived discomfort, such as pain and itching. However, the regulatory summary notes that a large volume of dedicated, modern, high-quality studies specifically for this exact combined formulation is lacking.

Q: Can Анузол be used for conditions other than those listed on the package?

A: The intended purpose of Анузол is strictly limited to the conditions and uses specifically described in the official regulatory labeling. Use for any conditions outside of those defined uses is not documented or supported by the official prescribing information.

Q: Does Анузол contain any steroids or hormones?

A: According to the official product information, Анузол contains three active ingredients: Belladonnae Folia Extract, Tribromphenolate Bismuth, and Zinc Sulfate. The official regulatory documents do not classify these specific active ingredients as steroids or hormones.

Q: Are there any food or drink interactions with Анузол?

A: A potential interaction with alcohol is described in official warnings. Since Анузол contains an ingredient classified as a central nervous system (CNS) depressant, co-administration with alcohol may potentiate the risk of increased CNS effects, such as drowsiness or sedation. No specific interactions with food are noted in the regulatory documents.

Q: What if I forget to use a dose of Анузол?

A: Regulatory guidance regarding a missed dose commonly addresses the scenario where a dose is remembered soon after the scheduled time. It also addresses how to proceed if the next scheduled dose is approaching, usually involving skipping the missed dose and continuing with the regular schedule. Official guidance notes that the amount used should not be doubled to make up for a missed dose.

Q: Does the time of day matter when using Анузол?

A: Official administration protocol specifies a key procedural condition: the suppository must be administered into the rectum only after a prior cleansing enema or a spontaneous bowel movement. While the documents state a frequency of one to three times per day, they do not mandate a specific time of day (such as morning or evening) beyond this procedural timing condition.

Q: Why is Анузол sometimes prescribed instead of creams?

A: Анузол is formulated as a rectal suppository. This specific dosage form is designed to deliver the active ingredients directly to the internal anorectal mucosa. This form allows for local action that distinguishes it from topical creams, which are primarily intended for external or surface application.

Q: Can children or teenagers use Анузол?

A: Official regulatory labeling restricts the use of Анузол to Adults only, defined as individuals 18 years and older. Use is formally not recommended in children and teenagers under 18 years, as safety and efficacy have not been established by regulators for these younger age groups.

Q: What kind of research has been done on the ingredients in Анузол?

A: The research base primarily focuses on the symptomatic effects of the combined, finished formulation. However, regulatory documents describe the established function of the individual components: the Belladonna component is classified as an anticholinergic agent, the Zinc Sulfate functions as a local astringent, and the Bismuth salt is described as having protective and mild antiseptic effects.

Official Storage and Disposal Requirements for Anuzol

Storage of Anuzol rectal suppositories must adhere to specific regulatory requirements to maintain product stability and safety.

Storage Conditions

The medicine should not be used past the expiration date marked on the packaging.

Disposal Instructions

Any unused or expired Anuzol must be disposed of in accordance with local regulatory requirements. Medicines should generally not be disposed of via wastewater or household waste unless specific local instructions advise otherwise.